Jazz Pharmaceuticals expands sleep disorder drug portfolio with FDA approval of Xywav
July 22, 2020 at 10:58 AM EDT
The company already markets two other narcolepsy drugs that generated more than $1 billion in combined sales last year.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|